Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose or Multiple Ascending Dose Study of KK4277 in Healthy Volunteers, Patient With Systemic Lupus Erythematosus, and Patient With Cutaneous Lupus Erythematosus

NCT05411016 is registered in ClinicalTrials.gov with Kyowa Kirin Co., Ltd. as lead sponsor.

NCT NCT05411016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose or Multiple Ascending Dose Study of KK4277 in Healthy Volunteers, Patient With Systemic Lupus Erythematosus, and Patient With Cutaneous Lupus Erythematosus
Lead sponsor
Kyowa Kirin Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 3, 2022
Completion date
October 27, 2025
Enrollment
125 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous lupus erythematosus (cle), healthy volunteers, systemic lupus erythematosus (sle)